Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia Pacific - Report - MDSpire

Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia Pacific

  • By

  • Charles Hua Chiang Siow

  • Shengyuan Yu

  • Surat Tanprawate

  • Shuu-Jiun Wang

  • Elspeth J. Hutton

  • Byung-Kun Kim

  • Min Kyung Chu

  • Norihiro Suzuki

  • Wanakorn Rattanawong

  • Ka Sing Wong

  • Mi Ji Lee

  • Zhao Dong

  • Hebo Wang

  • Xianliang Li

  • Koichi Hirata

  • Takao Takeshima

  • May 28, 2026

  • 0 min

Share

Clinical Report: Consensus on Migraine Diagnosis and Treatment in Asia-Pacific

Overview

A Delphi consensus involving 14 headache specialists in the Asia-Pacific region established key recommendations for migraine diagnosis and management. The study highlighted the use of ICHD-3 criteria and the effectiveness of anti-CGRP monoclonal antibodies in addressing unmet needs in migraine treatment.

Background

Migraine is a prevalent neurological disorder affecting approximately 15% of the adult population globally, with significant implications for quality of life and economic burden. Despite established diagnostic criteria and treatment guidelines, many patients remain undiagnosed or undertreated, particularly in the Asia-Pacific region. This consensus aims to improve clinical practices and address the gaps in migraine management.

Data Highlights

FindingPercentage
Used ICHD-3 for diagnosis93%
Found ICHD-3 easy to apply79%
Considered anti-CGRP mAbs effective86%
Believed anti-CGRP mAbs improve safety and adherence93%
Favored anti-CGRP mAbs as first-line treatment79%

Key Findings

  • Consensus reached on 12 of 21 statements regarding migraine management.
  • 93% of participants used ICHD-3 criteria for migraine diagnosis.
  • 86% considered anti-CGRP monoclonal antibodies effective for migraine prevention.
  • Efficacy, safety, and tolerability were the top factors in selecting anti-CGRP mAbs.
  • Participants unanimously supported the use of anti-CGRP mAbs in adolescents, but not in children under 12.

Clinical Implications

Clinicians in the Asia-Pacific region are encouraged to adopt ICHD-3 criteria for migraine diagnosis and consider anti-CGRP monoclonal antibodies as a first-line treatment option for adults and adolescents. The findings underscore the importance of addressing comorbid conditions such as anxiety and depression in migraine management.

Conclusion

The Delphi consensus provides a framework for improving migraine diagnosis and treatment in the Asia-Pacific region, emphasizing the need for adherence to established guidelines and the incorporation of effective therapies.

Related Resources & Content

  1. Frontiers | Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for Migraine in Asia Pacific
  2. IHS, ACP Differ on Migraine Tx
  3. Factors Influencing the Limited Effectiveness of Acute Migraine Treatments in Japan
  4. Can Migraine Care Be Reliably Measured?
  5. BMC Psychiatry (Springer) — Prevalence of migraine among adults with mood disorders: a Saudi cross-sectional study
  6. Frontiers | Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for Migraine in Asia Pacific
  7. 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies - PubMed
  8. International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine - PubMed
  9. Sex-specific management of migraine a systematic review and consensus statement from the European Headache Federation (EHF) - PubMed
  10. Calcitonin gene-related peptide (CGRP) -targeting antibodies as a first-line option for the prevention of migraine in adults: A Japanese Headache Society position statement
  11. Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network Meta-analysis - PubMed
  12. Dual-mechanism preventive therapy in chronic migraine: an exploratory meta-analysis of onabotulinumtoxinA and anti-CGRP monoclonal antibody combination | European Journal of Medical Research | Springer Nature Link
  13. IHC 2025 late-breaking abstracts, 2025
  14. AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention

Original Source(s)

Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia Pacific

  • by Charles Hua Chiang Siow, Shengyuan Yu, Surat Tanprawate, Shuu-Jiun Wang, Elspeth J. Hutton, Byung-Kun Kim, Min Kyung Chu, Norihiro Suzuki, Wanakorn Rattanawong, Ka Sing Wong, Mi Ji Lee, Zhao Dong, Hebo Wang, Xianliang Li, Koichi Hirata, Takao Takeshima

  • May 28, 2026

Related Content

Model May Reframe Tension-Type Headache

Proposed framework organizes interacting factors into four domains to guide personalized assessment

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Objective oculomotor, vestibular, reaction time, and cognitive signatures of vestibular migraine